portfolio resili intact lift pt
wm scenario aplenti consid strong gener
fsli impress guid fog growth rais
pt
color fundament focu call wm
like viru pangolin back materi delay
oxbryta first full quarter disappoint pt
headwind look less sever fear rais
invest strateg await asceniv ascent
report strong pt
analyst certif import disclosur see
continu attent move toward
phase advanc prostat cancer
high confid ultim covid recoveri liver data sound
quarterli updat offer variou put take
power pandem look ahead
updat voyag continu data ahead
review quarter complic year diversifi
review move along
offer detail eha dataflow
quick glanc
report driven retail
solid driven wfh trend rais pt
acceler secular on-line shift benefit
seller ecosystem pressur somewhat counterbalanc
drive massiv acceler product adopt
still earli inning
lower pt reduc estim
impact covid
first look trend strong result hurt
first look in-lin result in-lin pro-forma
headwind tailwind near term
result commentari lend support long
term beneficiari
quick read much better fear april comp deliveri
dlph updat model result
out-performance set navig market pt
manag pandem
record quarter amidst wreckag
built offens
wcn first look result
sustain growth resourc optim
portfolio resili intact lift pt
post result ahead street estim pull guidanc believ compani manag covid
complic well demonstr divers resili busi recur revenu reach mix
drove gm upsid recur revenu come field oper see daili use compani highlight
retent rate line pre-covid level sale cycl extend modestli management acceler effort bundl
hardwar softwar solut support custom intimaci margin proactiv manag cash
though multipl measur appear pois gain materi share recoveri reiter op rais pt
sustain growth resourc optim
wm scenario aplenti consid strong gener
wm report adj ep sharp consensu suspend guidanc uncertainti
like peer wm provid ampl data indic organ trend posit inflect late april higher floor
prior estim contempl howev compani opt extrapol earli trend view uncertainti
commerci recoveri still expect gener prove resili broad rang scenario revis
estim contempl sale declin rais sales/adj ep estim
maintain price target
cloud
fsli impress guid fog growth rais pt
fsli report strong increas revenu guidanc strong confid sustain high-profit
growth revenu grew y/i bp beat expect adj ebitda reach profit next quarter given strong
oper leverag model leverag softwar fsli abl gener increment revenu per one dollar
capital-expenditure among highest leverag seen long term fsli uniqu develop platform enabl applic
busi secur connect constitu extrem low latenc enabl next gener highli
interact edge-bas servic rais price target base revenu estim
support dcf model
analyt collabor infrastructur softwar
highlight divers custom base exposur broad grow rang use case grow relev digit
economi bode well twilio abil navig near-term volatil econom distress flex/
telehealth etc off-set affect vertic also sustain already-robust expans rate leav us
comfort twilio plan invest upsid catalyst ahead flex demand acceler healthcar
contribut grow presidenti elect remain bullish rais estim pt given result
reiter outperform drawn specialti rental model featur long-liv assets/lengthi rental durat
moder price point lend rel resili impact environ compani
outperform estimates/consensu top-to-bottom adjust ebitda grew year/year adjust ebitda
margin expand despit condit late quarter core storag segment revenu
units-on-r still y/i institut cost-sav adjust reduc
capital-expenditure grew leverag vs five quarter ago anticip
continu gener signific throughout maintain target
drawn specialti rental model featur long-liv assets/lengthi rental durat moder price point
lend rel resili environ instead opt withdraw guidanc
lowered/widen adjust ebitda rang still solid y/i enhanc transparency/depict
rel resili model support outlook sensit guid rang base macroeconom condit severity/
durat share lead indic data pend orders/ord schedul /enhanc end-market color posit
like healthcar partli offset unfavor opex capital-expenditure lever dispos per severity/dur sustain
ramp/delivered-spot-r vs average-monthly-r spread essenti exist portfolio price cushion vs spot volatil
wed may market close outperform-r carvana report result updat investor
upon step compani undertak contend on-going crisi
continu review close recent trend carvana within broader sector plan publish updat
overal view underli trend still solid look upon sale earn weak entir
function mid-mar onset coronaviru pandem us initi part manag off-set
adjust ep track last year vs street figur upon retail unit
sale
look beyond toward potenti forthcom abat crisi find key factor
particularli encourag share
use car unit sale alreadi start rebound meaning volum track vs end
data suggest eas use car price apt make compel inventori acquisit opportun well-
posit dealer
particularli well-situ serv need custom look contact-light use car shop experi
color fundament focu call wm
like viru pangolin back materi delay program
wednesday allogen report earn caught manag clinic busi oper
demonstr impress resili pandem manag expect deliv previously-guid
mileston anticip phase dose escal result least nhl patient enrol alpha trial
believ confer abstract slate public next week may omit key patient enrol late studi
allogen plan initi trial abbrevi dose escal studi could potenti
rapidli transit pivot phase trial separ first-in-human result studi multipl myeloma
mm remain track reiter outperform pt
oxbryta first full quarter disappoint pt
wednesday report earn discuss first full quarter oxbryta launch manag oxbryta
post sale revenu easili beat estim howev manag report notic
relat slowdown new script begin march yet bottom like dampen sale growth
regardless believ strong result point substanti demand oxbryta revis revenu
project despit pandem made headway on-board payer expect secur broad coverag
end enrol paus post-approv confirmatori trial label expans younger
pediatr patient remain near-term goal reiter outperform pt
headwind look less sever fear rais estim
report disclos improv cologuard test volum trend last day april
vs first day month result line pre-announce level revenu guidanc
expect investor attent next month focu potenti cologuard captur portion estim
screen colonoscopi month cancel due base case assum patient
simpli defer colonoscopi sever flare-up could drive peopl consid non-invasive altern
could drive market share cologuard short extend pandem would sure bad overal economi
might actual strengthen competit posit
invest strateg await asceniv ascent
revenu year/year vs con report materi impact suppli
chain global ivig suppli remain tight compani grow commerci plasma product busi continu
invest critic area infrastructur throughput personnel initi add expens believ
bring fill-finish in-hous expand fraction capac build addit collect center benefit
oper cost gross margin batch product cycl time beyond continu view asceniv launch
key outperform thesi given favor pricing/margin reduc pt await better visibl
sale trajectori follow extens revis model
report strong pt
alnylam revenu beat consensu estim impress onpattro sale growth
q/q solid initi show givlaari facilit robust patient access lower onpattro revenu
guidanc headwind mainli felt expens manag mitig bottom-lin impact
report favor clinic data aln-agt earli support develop prospect refractori hypertens
novel moa lumasiran inclisiran approv submiss two ind aln-cov aln-hsd track occur
year-end lumasiran pivot data present eu medic confer june lack capit market depend
follow recent blackston transact help insul broader market volatil reiter outperform pt
continu attent move toward phase advanc prostat cancer
detail updat data veru phase studi men metastat castration-resist prostat cancer mcrpc
show anti-tubulin signific therapeut potenti set along accept safeti
conveni oral dose although patient yet complet treatment evalu observ respons
durat month diseas stage strike phase anticip start ev
current capit need fulfil grow commerci revenu stream view veru attract reiter outperform
high confid ultim covid recoveri liver data sound excit
rev beat consensu estim ep loss cent light street
recal pull guid amid covid uncertainti despit expect continu
impact expect transmed non-elect essenti lifesav high-margin procedur pent-up demand
high prioriti staff icu bed becom avail look forward fda heart panel expect late
expect excit liver data support on-tim pma submiss come week state
initi believ oc system game changer organ transplant outcom econom
believ servic model add flexibl post-covid recoveri reiter outperform
sale ahead our/street estim better expect net afrezza
revenu y/i versu estim afrezza gm well estim sg
lower compani continu control personnel/market cost management note benefit
wholesaler/pati stocking-up advanc stay-at-hom order across countri expect neg impact
quickli implement digit tools/program support salesforc patient current environ tret
note call breez trial may slightli delay given paus patient enrol
expect impact approv timelin
quarterli updat offer variou put take
report financi result includ hcv royalti consensu
estim guidanc hcv sale drive royalti estim in-lin consensu
pipelin progress continu despit impact includ rsvp trial on-going data expect
addit rsv studi initi pbc intrepid trial miss primari endpoint
alp reduct normal although show clean safeti shift focu nash trial set dose
virem hbv studi initi follow-on fxr agonist studi initi
antivir discoveri work on-going maintain perform detail full report releas today
power pandem look ahead
report result ingrezza revenu easili outpac estim consensu
manag describ success effort navig pandem futur plan includ ingrezza script
volum grew sequenti adjust channel inventori chang base pre-author reset shift virtual
sale initi ingrezza new patient start held despit fewer offic visit off-set advanc telemedicin
ongenti launch prepar delay mention post-april fda approv exist clinic trial enrol paus
due new clinic trial on-track initi non-gaap sg spend guidanc widen
lower mid-point updat model maintain pt report detail
updat voyag continu data ahead
report result collabor revenu opex recent progress minim
disrupt outlook key pipelin catalyst remain intact includ trial on-going
new patient screen resum late pend restrict trial initi still
anticip data data expect read
hd develop updat expect addit preclin data expect abstract
featur vy-aadc technolog advantag preclin data hd al view
well-posit cash provid runway maintain outperform detail full report
updat model post result manag busi updat result lag consensu
estim primarili due lower spinraza royalti revenu manag maintain guidanc indic
anticip strong note manag remain confid current pandem affect pipelin
progress wholli own partner current valuat continu like stock offer diversifi
pipelin invest opportun along strong balanc sheet maintain outperform rate slightli lower pt
prior updat quarterli result
review quarter complic year diversifi qualiti pipelin
alexion report sales/earn provid investor updat compani comfort beat
opco below-consensu number commerci product exhibit strength especi ultomiri strensiq
howev manag downgrad sale guidanc due potenti slowdown
also reduc expect non-gaap opex spend recent purchas potenti qualiti asset portola
announc would expect non-gaap spend guidanc increas later year qualiti pipelin diversifi
away continu move apac major phase readout wilson diseas expect
adjust reflect on-going chang stay neutral
review move along
sarepta report result provid updat corpor progress net product revenu
report estim exhibit driven potenti disrupt
although breakdown individu product revenu eteplirsen golodirsen avail believ first full
quarter launch golodirsen affect lower expect new patient start asid execut across gene therapi
project dmd progress steadili lead catalyst worth stay mind modestli adjust
estim downward expect stabil close adjust lower total product
offer detail eha dataflow
report opex match estim cash project last
updat addit bet inhibitor data myelofibrosi mf present eha eha
abstract may detail expect patient number see insid view updat major catalyst base
significantli larger patient number impact mf trial enrol start-up activ initi
timelin remain track manifest amend mitig incomplet data collect focu regulatori strategi
sever option trial initi addit data prostar expect
expect priorit dose select ye
quick glanc
report adj ep primarili includ suppli cost
 cost well ahead opco/street estim compani overcam impact
estim pdgm top street expect cost control off-set impact see recap
compani estim segment growth impact total revenu impact total
suppli cost exclud earn due withdrew prior adj ep guidanc
flow op prior period balanc sheet remain clean
net debt-to-ebitda pro forma aseracar
report driven retail
report adj ep vs opco/street estim compani estim covid
pandem help result retail account major gain due robust march s- sale
meanwhil april aetna perform well util covid-driven top-lin strength
retail/pharmaci slow reflect variou put take covid includ higher interest expens
lower invest incom maintain ep guidanc withdrew underli
assumpt follow quarter maintain ep tweak ep
solid driven wfh trend rais pt
report revenu y/i beat street estimateconsist check
strong bill y/i swiftli exceed consensu estim suggest intact healthi
industri dynam amid crisi guidanc essenti line current street estim
prudent withdrawn given grow uncertainti despit solid april trend expect continu benefit
nt follow strong demand sd-wan forticlient/vpn authentication/token mid/high rang secur
applianc driven wfh branch offic access secur fabric adopt new product launch fortig
power processor solid execut across region rais pt reflect ev/
report street estim revenu ebitda ep nevertheless guidanc
significantli street estim given elong sale cycl headwind expens
convert industry-lead identivers confer virtual format withdrew revenu guidanc
current uncertain environ creat nt headwind see immedi wfh benefit believ
lt thesi remain larg intact display consist win across fortun serv multipl
vertic driven digit transform initi hybrid platform well posit displac legaci solut
post disciplin mid-teen revenu growth coupl mid-to-high-teen adjust ebitda growth maintain outperform trim
pt
demonstr quit strong busi execut evidenc new busi wins/partnership quarterli
result track essenti ahead expect thru mid-march shutdowns/lockdown meaning
impact merchant volum perhap peak recent trend y/i beyond merger
synergi target quickli taken action deliv increment annual cost save perhap
sustain longer term whilemerch growth significantli impact spend declin issuer
consum prove rel resili surprisingli provid updat guidanc remain
confid three-year cost/revenu synergi goal maintain outperform rais pt
acceler secular on-line shift benefit
consid headwind paypal deliv solid result cc revenu grew y/i ep
vs our/street estim impact increas credit reserv reflect cecl requir macro
account tpv growth deceler y/i cc reflect drag travel
ticket event perhap interest april saw dramat acceler vs march new account
add on-line commerc benefit global shelter-in-plac behavior manag believ secular shift toward
digit payment acceler year april revenue/tpv growth acceler respect
perhap conserv manag forecast fx revenu growth surprisingli pull ep
guidanc maintain outperform rate rais pt
seller ecosystem pressur somewhat counterbalanc app strength
squar deliv gross profit growth ex-caviar ebitda vs estim reflect larg
credit provis surprisingli seller ecosystem experienc signific pressur last two week
gpv y/i highlight y/i declin card-pres gpv notabl app gross profit grew y/
nomin impact transact profit grew y/i vs estim subscript servic
adjust revenu grew vs estimate benefit robust app capit seller subs/servic product
sq indic recent stabilization/improv within seller ecosystem app growth could pois
acceler remain impress sq strong growth notwithstand headwind estim review
rais target maintain outperform rate engag trend show
evolv pure on-line date social furthermor compani earli stage roll
stream video featur remain tailwind post time around return normal
date remain unknown revenu y/i ex-fx march vs feb revenu guidanc seem
conserv midpoint y/i ex-fx even though april manag said churn remain line pre-
level averag daili messag april vs final week feb demograph femal
engag increas male tinder video featur expect late
drive massiv acceler product adopt still earli inning
follow result increas target maintain outperform rate
acceler adopt at-hom connect fit yield signific near- medium-term benefit eop
connect fit sub y/i jun guid y/i demand increas significantli march follow
widespread shelter place ordin gym closur convers pipelin strong digit sub q/q
follow management decis provid free trial promot outlook surpass bullish street estim
revenu high end guid prior ahead street estimate comment suggest strong backlog
given connect fit sub tailwind faster path termin margin see pton moat becom wider
cloud
lower pt reduc estim impact covid
deliv mix quarter revenu y/i adj ebitda line estim manag
withdrew guidanc believ covid materi neg impact result year ebitda declin
rang second half year due rise custom churn bad debt expens posit compani
manag dividend pay-out lower capital-expenditure interest tax payment push debt matur
substanti lower interest cost suggest pay billion year debt posit digitizing/
autom busi much upgrad network put better posit lt
cloud
first look trend strong result hurt currency/tim supply/demand imbal posit
miss top-lin estim bp organ growth drop last quarter currenc
neg impact apac emea result margin line estim posit cloud internet compani
scrambl datacent space increas capac increas usag due increas demand
posit datacent industri suppli long lead time believ best posit due highli
interconnect ecosystem view linchpin next era comput edge/fog/hybrid affo per share grew
y/i vs estim
cloud
first look in-lin result in-lin pro-forma guidanc
t-mobil deliv solid quarter revenu y/i adj ebitda y/i expect compani
peer-lead postpaid phone subscrib addit churn posit compani rapidli deploy
spectrum own optim spectrum versu market share main focu t-mobil
abl mitig churn sprint subscrib base covid actual help regard store closur buildout
network less strain neg sprint subscrib base suscept churn econom downturn
provid histor financi full-year guidanc combin compani
report result headwind tailwind near term
report good result consensu posit momentum strong busi
ad net-new custom compani histori despit disrupt furthermor manag kept
guidanc lower confid withdraw guidanc stand think balanc busi
offer custom flexibl downgrad seat reduct flexibl payment term etc crisi minim churn
right thing believ howev creat bad optic growth revenu bill net-revenu
retent cash flow gener near-term bottom line sidelin data point
tailwind blow faster headwind maintain perform
analyt collabor infrastructur softwar
alteryx deliv results/bil larg line temper expect support normal start quarter
solid new custom addit yoy demand weaken march pace new business/expans hurt
higher churn longer sale cycl exposur impact vertic alteryx high up-front rev/rec profil compound
pressur result disappoint guidanc wider varianc clear deck
minim near-term risk believ investor also account potenti pressur critic quarter
annual renew activ longer term chang thesi believ exist growth driver new custom new
use case intern expans secular trend digit autom ai/ml remain intact adjust estim
base results/guid
highlight day appl suppli chain leav china digitim
china smartphon ap shipment brace steep drop say digitim research digitim
global sale slip say digitim
result commentari lend support long term beneficiari
ringcentr report strong result work-from-hom trend drove acceler busi commun
requir healthi big deal growth cash gener balanc quarterli out-performance trend
moder investor look given strengthen fundament bottom line result show
ringcentr short-term beneficiari current situat also benefit stock long-term
acceler emerg work-from-hom trend enterpris adopt mean strong multi-year run seen
share fuel consist beat-and-rais quarter back growth margin come ahead
consensu expect sustain note result display element reiter outperform rais target
analyz result speak manag continu promot top mid-cap idea new
breakfast daypart strongli mix sale prior increment breakfast benefit expect state
reopen impress current compstore trend appear close turn posit anticip recoveri
outperform peer beyond forecast posit earn revis street estim particularli given heavi
invest spend embed consensu reiter outperform rais target
quick read much better fear april comp deliveri
report flat april comp ex ga fx us ahead expect mid-singl digit declin us
compar sale exclud gasolin optic travel food court hear aid photo foreign exchang much
healthier increas restrict closur certain depart weigh meaning comp
perform e-commerc trend acceler april march februari
adjust estim reflect stronger april sale model fulli incorpor increment
expens junctur expect see meaning miss driven higher covid expens would take
advantag like continu volatil trade
compstore april highlight brand momentum benefit strong off-premis model digit current
sale vs pre-viru could prove sticki keep sale trend elev even state begin reopen
free deliveri promot april turn close monitor sale trend chang consum
begin bear cost deliveri rais sale ebitda earn estim expect street
believ fairli reflect stock valuat ev/ebitda maintain perform rate
report adj ep vs our/consensu estim beat driven stronger
anticip margin particularli europ despit sporad plant closur exhibit
manag withdrew full-year outlook due uncertainti outlin assumpt challeng
includ sale y/i oper margin m/hsd rang respons implement varieti cost
action variabl structur natur temporarili suspend share repurchas evalu addit action
necessari look color call regard timing/magnitud save
sustain growth resourc optim
dlph updat model result
follow announc pre-market amend transact agreement dlph report top-/bottom-
line result consensu estim indic cost transform plan ahead schedul amend
credit agreement organ sale declin y/i due lower global product closur custom product site
expect dlph quiet corpor commun front acquisit close parti continu
expect adjust forward estim result
sustain growth resourc optim
out-performance set navig market pt
beat top/bottom line consensu estim robust market outgrowth effect manag decrement
conserv guidanc spoke discount expect lvp product ramp least qtd prove
correct view amend transact agreement dlph view afford enhanc protect
market deterior enabl parti move forward net leverag ampl liquid balanc
sheet remain top-tier among auto supplier combin strong ytd executionnot start limit product
seneca sc three week tornado tore plantw believ continu support sector premium
valuat reiter outperform take price target
sustain growth resourc optim
manag pandem
report result indic see steadi increas lead video sale close rate appear
compani quickli return normal sale level believ two pinchpoint industri right
construct permit final inspect appear permit rate improv manag note ca seen
declin begin covid shutdown bounc back meanwhil
ne state initi begun recov inspect effici unclear although note pressur
complet project ca help avoid blackout like seen remain construct share due
proactiv manag industry-lead practic across organ
sustain growth resourc optim
sedg post strong result modestli ahead consensu guid revenu line gm bp
expect understand gm driven higher eu mix carri gm us due exchang
rate higher competit note lead time vari region area still ten week other normal
six understand guidanc assum sedg backlog current schedul deliveri defer suggest
guidanc meaning de-risk manag note strength commerci rooftop sale typic better
visibl residenti channel believ sedg key product advantag potenti substanti
outperform market remain construct share anticip margin recoveri lt sale growth
host call investor annual virtual oppenheim industri growth confer chief strategi
offic matthew fassler number execut includ ceo bradley jacob new cfo david wyshner
share view busi trend current environ well insight regard posit
emerg efficient/profit entiti
oper broad portfolio essenti transport logist servic keen focu e-commerc
exposur favor partial off-set adversely-impact end-market total compani revenu
april despit challeng condit near-term center upon keep employe safe serv
custom capit increment opportun util technolog advanc captur effici
manag oper capit expens continu gener ampl free cash flow like
appreci transpar oper prowess maneuv current challeng free cash flow profil
inexpens valuat likelihood ultim demonstr progress financi improv reiter outperform
report ebitda vs larg driven cost reduct product revenu
declin yoy owe tough comp product discontinu unfavor weather weaker demand product
ebitda decreas owe lower revenu base unfavor mix off-set weak
appear manag implement remain pace fulfil cost save program
separ compani end quarter cash hand drew-down revolv
owe uncertainti compani withdrew guidanc result lower ebitda
record quarter amidst wreckag
report fee-rel earn fre essenti line estim after-tax
realiz incom per common estim consensu repres quarter
mani record record manag fee fre y/i respect margin second-highest realiz
incom driven realiz activ record-break fpaum pass threshold although net accru
perform fee balanc declin q/q due headwind current econom environ also delay
realiz environ provid ampl opportun deploy capit impact earn well beyond out-
year estim fuel excel continu track record fre growth
built offens
result basic line expect clearli pressur fee incom signific
reduct carri incom come quarter share trade well flat day investor clearli
look beyond near-term earn interest factoid came call firm
invest sinc market volatil began februari credit equiti know exactli
much done despit heavi pace invest total uncal commit dri powder
increas year-end march
sustain growth resourc optim
wcn first look result
wcn beat top/bottom line consensu estim prior guidanc provid april preliminari financi
note solid wast trend inflect posit late month organ revenu declin april better
fear whole broad-bas improv across servic line month reson peer
commentari still temper optim could warrant given earli stage recoveri compani alreadi
decid trim budget capital-expenditure earn releas indic compani file tomorrow
addit inform recent solid wast trend may impact expect fy look detail
releas earn call et
may biotech summit featur chemistri life process institut chicago il virtual confer
